Autolus Therapeutics (NASDAQ:AUTL) Upgraded to “Buy” at The Goldman Sachs Group

The Goldman Sachs Group upgraded shares of Autolus Therapeutics (NASDAQ:AUTL) from a neutral rating to a buy rating in a report issued on Monday morning, MarketBeat Ratings reports. The brokerage currently has $7.60 target price on the stock, up from their previous target price of $7.00.

A number of other research analysts also recently issued reports on AUTL. Redburn Atlantic raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective on the stock in a research report on Friday. Needham & Company LLC reaffirmed a “buy” rating and issued a $9.00 price target on shares of Autolus Therapeutics in a report on Monday, November 11th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Autolus Therapeutics presently has an average rating of “Buy” and an average price target of $10.15.

Autolus Therapeutics Stock Down 2.9 %

Autolus Therapeutics stock opened at $2.99 on Monday. The firm has a market cap of $795.62 million, a P/E ratio of -2.47 and a beta of 2.04. The business has a fifty day moving average of $3.88 and a two-hundred day moving average of $3.98. Autolus Therapeutics has a twelve month low of $2.92 and a twelve month high of $7.45.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same period in the previous year, the firm posted ($0.26) earnings per share. Equities analysts expect that Autolus Therapeutics will post -0.94 earnings per share for the current year.

Institutional Trading of Autolus Therapeutics

Several large investors have recently bought and sold shares of the stock. Wellington Management Group LLP raised its holdings in shares of Autolus Therapeutics by 35.4% in the third quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock worth $87,919,000 after buying an additional 6,330,392 shares during the last quarter. State Street Corp raised its stake in Autolus Therapeutics by 1.7% in the 3rd quarter. State Street Corp now owns 606,544 shares of the company’s stock worth $2,202,000 after acquiring an additional 10,401 shares during the last quarter. HighVista Strategies LLC lifted its position in Autolus Therapeutics by 2.7% during the 3rd quarter. HighVista Strategies LLC now owns 533,024 shares of the company’s stock worth $1,935,000 after acquiring an additional 14,204 shares during the period. Erste Asset Management GmbH acquired a new stake in Autolus Therapeutics during the 3rd quarter worth about $708,000. Finally, Bellevue Group AG grew its stake in Autolus Therapeutics by 27.7% during the 3rd quarter. Bellevue Group AG now owns 41,500 shares of the company’s stock valued at $151,000 after purchasing an additional 9,000 shares during the last quarter. Hedge funds and other institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.